From CNN, 2022. Clinical trials that have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.
From John Hopkins - Reclassification Recommendations for Drug in ‘Magic Mushrooms’ 09/26/2018 If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV Psilocybe cubensis, a common variety of psilocybin-containing mushroom Credit: Paul Stamets In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control.
Lots of information here from the European Institute of Microdosing.
Including "How To", a lot of research, ,
Interesting article from Vice, but somewhat outdated, from 2015.
Microdosing, where people take miniscule amounts of substances to change patterns of behavior, has brought psychedelics to the mainstream.
Article from Rolling Stone, 2020
Promising results have been found for psilocybin microdosing, in reducing symptoms of depression as conventional treatment.
What??? From a government website?
Article from Forbes magazine, 2020
Psychedelics have returned from the fringes and entered the mainstream in a huge way, whether through successful ballot initiatives, on the stock market or in Silicon Valley. But today, it’s not profoundly visual, earth-shattering trips like the ones that inspired Steve Jobs to create the iPhone that are being hyped. It’s microdosing.
Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process